Aptevo details warrant terms as mipletamig shows 79% TP53-AML remission, $8.3M cash
A closer look at Aptevo's November financing shows up to $15 million in additional potential proceeds, as the company highlights mipletamig data ahead of a 2027 FDA meeting.
SEC filing, FDA (7)